The Singapore Government has identified biotechnology as one of the four pillars of the economy for the twenty‐first century. For the last forty years, Singapore has pursued a very successful economic growth strategy of attracting investment from leading multinationals through a combination of financial incentives, world‐class infrastructure, a highly literate workforce and a business‐friendly regulatory environment. In the biotechnology industry worldwide, however, the typical development pattern has been very different: new start‐up companies backed by venture capitalists clustered around leading research universities. This article examines the development of the biotechnology cluster in Singapore, showing how a modified version of Singapore's traditional growth model is co‐existing with a more typical biotechnology development pattern.
No takes yet. Share an insight, caveat, or question.
Finegold et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: